Fortrea Q3'26 Earnings Conference Call - FORTREA HOLDINGS INC

Financial Performance:

• Q3 2026 revenue was $691.5 million, down 1.4% year-over-year but up 2.0% sequentially.
• Adjusted EBITDA reached $58.0 million (8.4% margin), up 14.4% YoY and slightly down 1.2% sequentially; YTD margin expanded 160 basis points to 8.2%.
• Net income was $0.6 million, a significant improvement from a $15.9 million loss YoY; Adjusted net income was $27.9 million.
• EPS was $0.29 basic and $0.28 diluted, compared to $0.13 and $0.12 respectively in the prior year quarter.
• Operating cash flow was $60.8 million and free cash flow was $52.5 million for the quarter; YTD FCF was positive $47.4 million.
• Net DSO improved significantly to 15 days from 33 days YoY and 20 days sequentially.
• Gross debt was $1.066 billion with net debt at $845.7 million, resulting in a net leverage ratio of 3.9x (improved 1.4x over the last 12 months).
• Backlog was adjusted downward by $558 million to $7.3 billion to reflect a more accurate estimation of remaining revenue, a move not impacting reported revenue guidance.
• Book-to-bill ratio was 1.12x for the quarter and trailing 12 months.
• Customer concentration decreased, with the top 10 customers representing 53.5% of revenue versus 60.0% YoY.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $2.665 billion–$2.690 billion; Adjusted EBITDA guidance raised to $211 million–$218 million.
• Guidance ranges for both revenue and EBITDA were narrowed, and midpoints increased.
• Full-year 2027 guidance was not provided; management expects continued recovery in bookings to drive 2027 growth.
• Q4 2026 is expected to see a slight sequential revenue slowdown due to fewer working days and higher IT OPEX investments.
• Long-term margin target remains "mid-teens" adjusted EBITDA margins.
• Management anticipates margin expansion driven by favorable business mix, improved utilization, technology adoption (FIT/AI), and operating leverage.

Business Segments and Product Lines:

• Completed acquisition of the early-phase services business from Worldwide Clinical Trials, adding bioanalytical and safety lab capabilities.
• Total clinical pharmacology bed count across the U.S. and U.K. expanded to over 570 beds, including a 300-bed Texas network.
• New in-house bioanalytical lab in Austin converts pass-through costs to service fee revenue.
• Launched "Fortria Intelligent Technology" (FIT), integrating AI, machine learning, and analytics; CRA mobile app deployed in 49+ countries.
• Internal AI literacy program "Felix" has seen >95% employee adoption.
• Biotech bookings grew nearly double-digit in 2026; Biopharma recovery is accelerating with increased RFP inflows.
• Strong pipeline growth across therapeutic areas, geographies, and customer types (large pharma, biotech, China-to-global).

Market and Competitive Landscape:

• Market environment characterized as "square in the middle of a recovery" with consistent RFP flow from both biotech and biopharma sectors.
• China remains a meaningful growth driver; no impact from the proposed COINS Act on current business dynamics.
• Fortria competes effectively in China with multinational sponsors and Chinese biotechs expanding globally.
• Scale remains a critical factor for biopharma customers, favoring top-tier CROs with global footprints.
• Pipeline value is broader and stronger than at any previous point, indicating a stronger competitive position.

Risks and Challenges:

• Backlog cancellations were slightly elevated but within normal bounds; a portion of the $558M adjustment involved "not-to-deliver" dynamics and inactive studies.
• Gross margin improvement is partially offset by increased compensation investments (~200 bps headwind).
• Interest expense increased sequentially due to higher benchmark rates on variable rate debt, despite YoY reduction from debt paydowns.
• Operational execution consistency (project management, enrollment, quality) remains a key challenge to convert backlog into revenue and protect margins.
• Foreign currency headwinds impacted YTD results by 60 basis points.

Management Commentary and Tone:

• Tone is confident and optimistic regarding the market recovery and the company's strategic execution.
• CEO Anshul Thakral emphasizes a "three pillars" strategy: commercial, operational, and financial excellence.
• New CFO Jason Knobloch expressed strong support for the customer experience focus and cost optimization initiatives.
• Management views the backlog adjustment as a necessary step for accuracy rather than a negative signal, noting it does not impact near-term revenue modeling.
• Strategic focus remains on "profitable growth" rather than growth at any cost, leveraging existing infrastructure for operating leverage.

Analyst Questions and Answers:

• EBITDA Guidance: Q4 guidance reflects fewer working days and a temporary step-up in IT OPEX, not a fundamental demand issue.
• Worldwide Acquisition: Integration is underway with a focus on embedding the business into the commercial pipeline; first award for new bioanalytical services secured immediately post-close.
• Backlog Adjustment: The adjustment includes both inactive studies and contracts with "not-to-deliver" dynamics; it ensures backlog reflects remaining life revenue and does not alter revenue recognition variables.
• Margin Trajectory: Gross margin expansion is driven by portfolio mix (higher economics) and operational efficiencies; mid-teens margin remains the target.
• CPS Sales Cycle: Clinical pharmacology sales cycles are shorter (weeks to months) compared to global clinical development, with faster study burn rates.
• China Market: Growth in China continues to be positive for both multi-nationals and Chinese biotechs going global; geopolitical legislation is not currently impacting operations.
• M&A Strategy: The Worldwide Clinical Trials acquisition is the "first step" in a long journey; Fortria remains open to further inorganic and organic investments to fill capability gaps.

Other Key Points:

• Management will participate in the Jefferies Global Healthcare Conference in London on November 17th.
• The company maintains ample liquidity (~$668M available) with no revolver borrowings outstanding.
• The strategic goal is to become the "CRO of choice for evidence generation," covering the full spectrum from first-in-human to post-approval.
• 2026 saw 600 basis points of gross margin expansion year-over-year despite headwinds.
• The "human-in-the-lead" approach remains central, with technology viewed as a force multiplier rather than a replacement for judgment.